G Poovi
Mother Theresa Post Graduate and Research Institute of Health Sciences, India
Title: Challenges and advances in solid lipid nanoparticle drug delivery systems
Biography
Biography: G Poovi
Abstract
In recent decades, a variety of pharmaceutical research projects have been conducted to develop new dosage forms, but the field of drug development experiences very low success rates with regards to drugs that enter the market, also it has become more and more evident that the development of new drugs alone is not sufficient to ensure progress in drug therapy. Exciting experimental data obtained in vitro are very often followed by disappointing results in vivo. Main reasons for the therapeutic failure include poor drug solubility leading to lowered bioavailability, insufficient drug concentration, high fluctuation of drug plasma levels, toxicity of the therapeutic compounds and thus reduced efficacy. Various approaches have been explored to address these challenges with little success. Scientific community believe that nanotechnology based drug delivery system offers new ways to address residual scientific concerns for the treatment of many diseases. In nanotechnology based drug delivery system, the Solid Lipid Nanoparticles (SLNs) are a new form of interesting nanoparticulate or lipid based drug delivery carriers in addition to the more conventional ones such as liposomes, lipid emulsions and polymeric nanoparticles. The potential advantages include: the possibility of controlled, sustained or prolonged drug release and drug targeting, increased drug stability, high drug payload, non - biotoxicity of the carriers, avoidance of organic solvents, suitability for large scale production and sterilization. Moreover, SLN promotes the oral absorption of poorly water soluble lipophilic drugs and enhances the bioavailability. The addition of PEGylation molecules prevents immune-protein adsorption and minimizes phagocytic uptake by macrophages, thus increasing blood plasma circulation time. An additional advantage involves the production of SLN in a powder form, which may be loaded into pellets, capsules or tablets for further enhancement of drug delivery.